Hoth Therapeutics (NASDAQ:HOTH) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Hoth Therapeutics (NASDAQ:HOTH) from a sell rating to a hold rating in a report published on Saturday morning.

Separately, D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a report on Thursday, June 26th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hoth Therapeutics currently has an average rating of “Buy” and an average target price of $4.00.

Hoth Therapeutics Stock Performance

NASDAQ:HOTH opened at $1.21 on Friday. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80. The firm has a market cap of $15.92 million, a P/E ratio of -1.06 and a beta of 0.67. The firm has a 50-day simple moving average of $1.06 and a 200-day simple moving average of $1.07.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.07. On average, research analysts predict that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC increased its position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,946 shares of the company’s stock after acquiring an additional 13,038 shares during the quarter. Geode Capital Management LLC owned about 1.39% of Hoth Therapeutics worth $72,000 as of its most recent SEC filing. Institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.